S&P Futures
4,268.75 -8.00 (-0.19%) Dow Futures
33,924.00 -39.00 (-0.11%) Nasdaq Futures
13,455.00 -38.25 (-0.28%) Russell 2000 Futures
1,986.70 -2.40 (-0.12%) Crude Oil
87.73 -0.38 (-0.43%) Gold
1,779.00 +2.30 (+0.13%)
Lucira Health, Inc. (LHDX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.8300 |
| Open | 3.0000 |
| Bid | 2.2500 x 900 |
| Ask | 2.3500 x 900 |
| Day's Range | 2.2500 - 2.8000 |
| 52 Week Range | 1.3600 - 10.6500 |
| Volume | |
| Avg. Volume | 66,535 |
| Market Cap | 90.609M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9900 |
| Earnings Date | Nov 09, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
- Motley Fool
Lucira Health, Inc. (LHDX) Q2 2022 Earnings Call Transcript
Earlier today, Lucira Health released financial results for the second quarter ended June 30, 2022. Joining me on today's call are Erik Engelson, president and chief executive officer; and Dan George, chief financial officer.
- GlobeNewswire
Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates
EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the seco
- Simply Wall St.
A Lucira Health, Inc. (NASDAQ:LHDX) insider increased their holdings by 11% last year
Insiders were net buyers of Lucira Health, Inc.'s ( NASDAQ:LHDX ) stock during the past year. That is, insiders bought...
